Innovative Digital Pathology Aperio's advanced ePathology solutions that digitize glass slides and enable remote collaboration present significant opportunities to expand sales within hospital pathology labs, research institutions, and pharmaceutical companies seeking to modernize their diagnostic workflows.

Strategic Acquisition Advantage Having been acquired by BlackRock and previously by Golden Gate Capital, Aperio benefits from strong financial backing and strategic positioning, making it attractive to institutional clients looking for stable, innovative vendors in medical imaging and diagnostics.

Growing Market Presence With recent awards and recognition such as the 2026 Product of the Year, Aperio is elevating its brand visibility, which can be leveraged to target new hospital networks and research organizations interested in cutting-edge digital pathology solutions.

Technology Leadership Aperio's extensive patent portfolio and history of high-speed scanning technology position it as a technology leader, creating opportunities to upsell existing clients or partner with organizations requiring scalable, interoperable, secure digital pathology systems.

Revenue Expansion Potential Operating in a niche within the medical equipment manufacturing industry with revenue between 10 million and 25 million, Aperio offers opportunities for targeted upselling and cross-selling to healthcare providers and labs upgrading their pathology infrastructure.